KR970704426A - 오메프라졸의 마그네슘 염을 함유한 신규의 경구 제약 제형(New Oral Pharmaceutical Formulation Containing Magnesium Salt of Omeprazole) - Google Patents

오메프라졸의 마그네슘 염을 함유한 신규의 경구 제약 제형(New Oral Pharmaceutical Formulation Containing Magnesium Salt of Omeprazole) Download PDF

Info

Publication number
KR970704426A
KR970704426A KR1019970700059A KR19970700059A KR970704426A KR 970704426 A KR970704426 A KR 970704426A KR 1019970700059 A KR1019970700059 A KR 1019970700059A KR 19970700059 A KR19970700059 A KR 19970700059A KR 970704426 A KR970704426 A KR 970704426A
Authority
KR
South Korea
Prior art keywords
formulation
omeprazole
enteric
core material
mammals
Prior art date
Application number
KR1019970700059A
Other languages
English (en)
Korean (ko)
Inventor
시프 인가 벤그트손
쿠르트 인그마르 뢰프그렌
Original Assignee
클래스 빌헬름슨
아스트라 악티에볼라그
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 클래스 빌헬름슨, 아스트라 악티에볼라그 filed Critical 클래스 빌헬름슨
Publication of KR970704426A publication Critical patent/KR970704426A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
KR1019970700059A 1994-07-08 1995-07-05 오메프라졸의 마그네슘 염을 함유한 신규의 경구 제약 제형(New Oral Pharmaceutical Formulation Containing Magnesium Salt of Omeprazole) KR970704426A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SEPCT/SE94/00679 1994-07-08
SE9400679 1994-07-08
PCT/SE1995/000816 WO1996001622A1 (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Publications (1)

Publication Number Publication Date
KR970704426A true KR970704426A (ko) 1997-09-06

Family

ID=20393105

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970700059A KR970704426A (ko) 1994-07-08 1995-07-05 오메프라졸의 마그네슘 염을 함유한 신규의 경구 제약 제형(New Oral Pharmaceutical Formulation Containing Magnesium Salt of Omeprazole)

Country Status (15)

Country Link
EP (1) EP0768872A1 (fi)
KR (1) KR970704426A (fi)
BR (1) BR9508261A (fi)
CA (1) CA2193681A1 (fi)
CZ (1) CZ379596A3 (fi)
EE (1) EE03378B1 (fi)
FI (1) FI970058A (fi)
HU (1) HUT78132A (fi)
IS (1) IS4398A (fi)
MX (1) MX9700152A (fi)
NO (1) NO970036D0 (fi)
NZ (1) NZ289958A (fi)
PL (1) PL181265B1 (fi)
SK (1) SK166096A3 (fi)
WO (1) WO1996001622A1 (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5900258A (en) * 1996-02-01 1999-05-04 Zeolitics Inc. Anti-bacterial compositions
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
AU3762801A (en) * 2000-03-09 2001-09-17 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
CA2771725C (en) 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1755566A2 (en) * 2004-06-15 2007-02-28 Teva Pharmaceutical Industries Ltd Stable pharmaceutical formulations of benzimidazole compounds
CN105106168B (zh) * 2015-08-19 2018-03-06 德州德药制药有限公司 一种埃索美拉唑镁肠胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation

Also Published As

Publication number Publication date
SK166096A3 (en) 1997-09-10
AU695723B2 (en) 1998-08-20
IS4398A (is) 1996-12-17
EE03378B1 (et) 2001-04-16
NZ289958A (en) 1998-09-24
NO970036L (no) 1997-01-06
MX9700152A (es) 1997-04-30
NO970036D0 (no) 1997-01-06
EE9700014A (et) 1997-06-16
WO1996001622A1 (en) 1996-01-25
HUT78132A (hu) 2000-06-28
FI970058A0 (fi) 1997-01-07
WO1996001622A8 (en) 1999-12-23
CZ379596A3 (en) 1997-08-13
EP0768872A1 (en) 1997-04-23
HU9700039D0 (en) 1997-02-28
FI970058A (fi) 1997-01-07
BR9508261A (pt) 1997-12-23
CA2193681A1 (en) 1996-01-25
AU2994795A (en) 1996-02-09
PL181265B1 (pl) 2001-06-29
PL318464A1 (en) 1997-06-09

Similar Documents

Publication Publication Date Title
KR970704426A (ko) 오메프라졸의 마그네슘 염을 함유한 신규의 경구 제약 제형(New Oral Pharmaceutical Formulation Containing Magnesium Salt of Omeprazole)
RU96102154A (ru) Новая фармацевтическая композиция, способ ее получения, способ лечения заболеваний с использованием композиции
KR870009717A (ko) 신규 경구용 약제
KR880002673B1 (ko) 진통 캡슐제와 그 제조방법
JP4907765B2 (ja) 経口医薬パルス放出剤形
TWI232755B (en) Oral medicament, and a supporting substrate complex of oral medicament
US4309405A (en) Sustained release pharmaceutical compositions
EP1162975B1 (en) Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
US5409709A (en) Antipyretic analgesic preparation containing ibuprofen
US4505890A (en) Controlled release formulation and method
DK158562B (da) Diffusionsovertrukket polydepotpraeparat og fremgangsmaade til fremstilling deraf
CA2835364C (en) Pharmaceutical composition of rosuvastatin calcium
KR870009718A (ko) 경구용 산에 불안정한물질의 약제
KR100429489B1 (ko) 위장관에서의 활성 화합물의 방출을 조절하기 위한 로젠지
US5397574A (en) Controlled release potassium dosage form
JP2007532689A (ja) 医薬有効成分の遅延性かつ調節性放出のための微粒子経口ガレヌス製剤
IL121652A (en) Pharmaceutical dosage forms for oral administration that include a proton pump inhibitor and a prokinetic substance
PT96078A (pt) Processo de preparacao de composicoes farmaceuticas contendo cimetidina
PT101085B (pt) Novas formas de dosagem de risedronato
JPS61275211A (ja) 治療薬粒子
JPH09504280A (ja) センナ剤形
NO157805B (no) Fremgangsmaate for fremstilling av et preparat for behandling av urinveisinfeksjoner.
KR20190092805A (ko) 아세틸살리실산 및 란소프라졸을 포함하는 약학적 조성물
GB2132887A (en) Enteric-coated anti-inflammatory compositions
JP3170855B2 (ja) イブプロフェン含有解熱鎮痛剤

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application